CN105288602A - 具有γ干扰素的抗原呈递癌症疫苗 - Google Patents
具有γ干扰素的抗原呈递癌症疫苗 Download PDFInfo
- Publication number
- CN105288602A CN105288602A CN201510706438.6A CN201510706438A CN105288602A CN 105288602 A CN105288602 A CN 105288602A CN 201510706438 A CN201510706438 A CN 201510706438A CN 105288602 A CN105288602 A CN 105288602A
- Authority
- CN
- China
- Prior art keywords
- cell
- melanoma
- ifn
- autophagy
- apoptosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 title claims description 56
- 108091007433 antigens Proteins 0.000 title claims description 56
- 102000036639 antigens Human genes 0.000 title claims description 56
- 229940022399 cancer vaccine Drugs 0.000 title description 3
- 238000009566 cancer vaccine Methods 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims abstract description 298
- 201000001441 melanoma Diseases 0.000 claims abstract description 202
- 108010074328 Interferon-gamma Proteins 0.000 claims abstract description 168
- 238000000034 method Methods 0.000 claims abstract description 166
- 102100037850 Interferon gamma Human genes 0.000 claims abstract description 149
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 126
- 229960003130 interferon gamma Drugs 0.000 claims abstract description 22
- 230000004987 nonapoptotic effect Effects 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 230000002886 autophagic effect Effects 0.000 claims abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 82
- 229960005486 vaccine Drugs 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 32
- 230000004083 survival effect Effects 0.000 claims description 27
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 16
- 238000000338 in vitro Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 9
- 230000005867 T cell response Effects 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000036755 cellular response Effects 0.000 claims description 5
- 230000003442 weekly effect Effects 0.000 claims description 5
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims description 4
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims description 4
- 230000032823 cell division Effects 0.000 claims description 4
- 230000003308 immunostimulating effect Effects 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 230000007774 longterm Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims 3
- 229940115256 melanoma vaccine Drugs 0.000 claims 3
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 229940030325 tumor cell vaccine Drugs 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 30
- 230000004900 autophagic degradation Effects 0.000 description 106
- 230000006907 apoptotic process Effects 0.000 description 101
- 230000008569 process Effects 0.000 description 100
- 210000004881 tumor cell Anatomy 0.000 description 80
- 108090000623 proteins and genes Proteins 0.000 description 47
- 230000004044 response Effects 0.000 description 38
- 206010028980 Neoplasm Diseases 0.000 description 34
- 230000014509 gene expression Effects 0.000 description 30
- 230000006698 induction Effects 0.000 description 22
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 102000008070 Interferon-gamma Human genes 0.000 description 19
- 238000000684 flow cytometry Methods 0.000 description 18
- 238000011160 research Methods 0.000 description 18
- 230000001568 sexual effect Effects 0.000 description 18
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 17
- 230000001640 apoptogenic effect Effects 0.000 description 17
- 102000005962 receptors Human genes 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 17
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 16
- 210000001744 T-lymphocyte Anatomy 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 102000011727 Caspases Human genes 0.000 description 14
- 108010076667 Caspases Proteins 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 102100035793 CD83 antigen Human genes 0.000 description 13
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 13
- 210000002950 fibroblast Anatomy 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000003053 immunization Effects 0.000 description 11
- 238000002649 immunization Methods 0.000 description 11
- 229940029030 dendritic cell vaccine Drugs 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 9
- 102000006381 STAT1 Transcription Factor Human genes 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 8
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- 230000035800 maturation Effects 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 108090000672 Annexin A5 Proteins 0.000 description 7
- 102000004121 Annexin A5 Human genes 0.000 description 7
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 210000000822 natural killer cell Anatomy 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 6
- -1 Mel-2 Proteins 0.000 description 6
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 210000004957 autophagosome Anatomy 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 6
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 description 5
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 5
- 102000015636 Oligopeptides Human genes 0.000 description 5
- 108010038807 Oligopeptides Proteins 0.000 description 5
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 5
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 5
- 230000030741 antigen processing and presentation Effects 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 239000003431 cross linking reagent Substances 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 238000007667 floating Methods 0.000 description 5
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N furocoumarin Natural products C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000004068 intracellular signaling Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 4
- 108050008874 Annexin Proteins 0.000 description 4
- 102000000412 Annexin Human genes 0.000 description 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 4
- 108010010995 MART-1 Antigen Proteins 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 230000015788 innate immune response Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 102100037907 High mobility group protein B1 Human genes 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 3
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 description 3
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 3
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 description 3
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 3
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000005482 chemotactic factor Substances 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000001325 log-rank test Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000003463 organelle Anatomy 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- 102000001477 Deubiquitinating Enzymes Human genes 0.000 description 2
- 108010093668 Deubiquitinating Enzymes Proteins 0.000 description 2
- 101100129915 Escherichia coli (strain K12) melB gene Proteins 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 2
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108091054729 IRF family Proteins 0.000 description 2
- 102000004289 Interferon regulatory factor 1 Human genes 0.000 description 2
- 108090000890 Interferon regulatory factor 1 Proteins 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102100026371 MHC class II transactivator Human genes 0.000 description 2
- 108700002010 MHC class II transactivator Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 description 2
- 102100024779 Suppressor of cytokine signaling 1 Human genes 0.000 description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004961 autolysosome Anatomy 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 210000000448 cultured tumor cell Anatomy 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 229960000235 temsirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 101100243447 Arabidopsis thaliana PER53 gene Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100021984 C-C motif chemokine 4-like Human genes 0.000 description 1
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
- DHAHOOFKGDKRGM-UHFFFAOYSA-N CCC.I(=O)(=O)O Chemical compound CCC.I(=O)(=O)O DHAHOOFKGDKRGM-UHFFFAOYSA-N 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 101100045694 Caenorhabditis elegans art-1 gene Proteins 0.000 description 1
- 101100327692 Caenorhabditis elegans hsp-60 gene Proteins 0.000 description 1
- 101100457021 Caenorhabditis elegans mag-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- 102100035037 Calpastatin Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 229920002160 Celluloid Polymers 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 102000006579 Chemokine CXCL10 Human genes 0.000 description 1
- 108010008978 Chemokine CXCL10 Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 1
- 102100031618 HLA class II histocompatibility antigen, DP beta 1 chain Human genes 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 description 1
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 description 1
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
- 108010093061 HLA-DPA1 antigen Proteins 0.000 description 1
- 108010045483 HLA-DPB1 antigen Proteins 0.000 description 1
- 108010086786 HLA-DQA1 antigen Proteins 0.000 description 1
- 108010065026 HLA-DQB1 antigen Proteins 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101001032334 Homo sapiens Immunity-related GTPase family M protein Proteins 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 101000983747 Homo sapiens MHC class II transactivator Proteins 0.000 description 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000043138 IRF family Human genes 0.000 description 1
- 102100038249 Immunity-related GTPase family M protein Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102100036157 Interferon gamma receptor 2 Human genes 0.000 description 1
- 102100029838 Interferon regulatory factor 2 Human genes 0.000 description 1
- 108090000908 Interferon regulatory factor 2 Proteins 0.000 description 1
- 102100038251 Interferon regulatory factor 9 Human genes 0.000 description 1
- 101710157824 Interferon regulatory factor 9 Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 108700005092 MHC Class II Genes Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 101150024075 Mapk1 gene Proteins 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100067996 Mus musculus Gbp1 gene Proteins 0.000 description 1
- 101001032335 Mus musculus Immunity-related GTPase family M protein 1 Proteins 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710175727 Peptide chain release factor 1 Proteins 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 102000004433 Proto-Oncogene Proteins c-pim-1 Human genes 0.000 description 1
- 108010017121 Proto-Oncogene Proteins c-pim-1 Proteins 0.000 description 1
- 101150094092 STAT1 gene Proteins 0.000 description 1
- 101150045565 Socs1 gene Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 1
- 102100024283 Suppressor of cytokine signaling 3 Human genes 0.000 description 1
- 102000000763 Survivin Human genes 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- 102000006463 Talin Human genes 0.000 description 1
- 108010083809 Talin Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102100030859 Tissue factor Human genes 0.000 description 1
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 description 1
- 102100023895 Zyxin Human genes 0.000 description 1
- 108010023249 Zyxin Proteins 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012822 autophagy inhibitor Substances 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 108010044208 calpastatin Proteins 0.000 description 1
- ZXJCOYBPXOBJMU-HSQGJUDPSA-N calpastatin peptide Ac 184-210 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(C)=O)[C@@H](C)O)C1=CC=C(O)C=C1 ZXJCOYBPXOBJMU-HSQGJUDPSA-N 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 108010085650 interferon gamma receptor Proteins 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000004576 lipid-binding Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000010949 lymph node disease Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 108010017286 macrophage inflammatory protein 1alpha receptor Proteins 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000017111 nuclear migration Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000001521 two-tailed test Methods 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549681P | 2011-10-20 | 2011-10-20 | |
| US61/549681 | 2011-10-20 | ||
| US201261594304P | 2012-02-02 | 2012-02-02 | |
| US61/594304 | 2012-02-02 | ||
| CN201280051821.7A CN103957925A (zh) | 2011-10-20 | 2012-10-22 | 具有γ干扰素的抗原呈递癌症疫苗 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280051821.7A Division CN103957925A (zh) | 2011-10-20 | 2012-10-22 | 具有γ干扰素的抗原呈递癌症疫苗 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105288602A true CN105288602A (zh) | 2016-02-03 |
Family
ID=48141460
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510706438.6A Pending CN105288602A (zh) | 2011-10-20 | 2012-10-22 | 具有γ干扰素的抗原呈递癌症疫苗 |
| CN201610218244.6A Withdrawn CN105861437A (zh) | 2011-10-20 | 2012-10-22 | 抗原呈递癌症疫苗 |
| CN201610301904.7A Pending CN105999249A (zh) | 2011-10-20 | 2012-10-22 | 具有γ干扰素的抗原呈递癌症疫苗 |
| CN201280051799.6A Pending CN103917246A (zh) | 2011-10-20 | 2012-10-22 | 抗原呈递癌症疫苗 |
| CN201280051821.7A Pending CN103957925A (zh) | 2011-10-20 | 2012-10-22 | 具有γ干扰素的抗原呈递癌症疫苗 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610218244.6A Withdrawn CN105861437A (zh) | 2011-10-20 | 2012-10-22 | 抗原呈递癌症疫苗 |
| CN201610301904.7A Pending CN105999249A (zh) | 2011-10-20 | 2012-10-22 | 具有γ干扰素的抗原呈递癌症疫苗 |
| CN201280051799.6A Pending CN103917246A (zh) | 2011-10-20 | 2012-10-22 | 抗原呈递癌症疫苗 |
| CN201280051821.7A Pending CN103957925A (zh) | 2011-10-20 | 2012-10-22 | 具有γ干扰素的抗原呈递癌症疫苗 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9555058B2 (enExample) |
| EP (2) | EP2768519A4 (enExample) |
| JP (2) | JP2014530627A (enExample) |
| KR (2) | KR20150016200A (enExample) |
| CN (5) | CN105288602A (enExample) |
| AU (2) | AU2012325764A1 (enExample) |
| CA (2) | CA2852960A1 (enExample) |
| HK (2) | HK1201176A1 (enExample) |
| IL (2) | IL232173A0 (enExample) |
| SG (4) | SG11201401631VA (enExample) |
| WO (2) | WO2013059784A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118441033A (zh) * | 2024-04-24 | 2024-08-06 | 广西医科大学 | HLA-DPB1*05:01在抗γ干扰素自身抗体所致获得性免疫缺陷筛查中的应用 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2865830B1 (fr) | 2004-01-30 | 2006-05-19 | Neopost Ind | Systeme d'affranchissement de courrier a mode d'impression externe securise |
| CN105288602A (zh) | 2011-10-20 | 2016-02-03 | 新干细胞肿瘤学有限责任公司 | 具有γ干扰素的抗原呈递癌症疫苗 |
| CN103599528B (zh) * | 2013-12-04 | 2015-08-05 | 深圳市合一康生物科技股份有限公司 | 人树突状细胞疫苗的制备方法 |
| JP6967963B2 (ja) * | 2014-07-17 | 2021-11-17 | ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. | 複数用量注射準備済樹状細胞ワクチンの製造ならびにｈｅｒ２およびｈｅｒ３を遮断するための併用療法 |
| KR20180126085A (ko) * | 2016-05-05 | 2018-11-26 | 난토믹스, 엘엘씨 | 체크포인트 부전 및 그 방법(checkpoint failure and methods therefor) |
| CA3053939A1 (en) * | 2017-02-17 | 2018-08-23 | Aivita Biomedical, Inc. | Methods to enhance tumor immunogenicity and compositions for autologous cancer immunotherapeutic products using modified tumor cells and modified dendritic cells |
| WO2024107624A1 (en) * | 2022-11-14 | 2024-05-23 | Shattuck Labs, Inc. | Methods of overcoming resistance to checkpoint inhibitor therapies |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080031900A1 (en) * | 2006-06-30 | 2008-02-07 | Baylor Research Institute | Dendritic Cells Generated Using GM-CSF and Interferon Alpha and Loaded with Heat-Treated and Killed Cancer Cells |
| US20090041792A1 (en) * | 2007-07-19 | 2009-02-12 | Istituto Superiore Di Sanita | Dendritic cells, uses therefor, and vaccines and methods comprising the same |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0598998B1 (en) * | 1992-09-07 | 2004-05-19 | Kyowa Hakko Kogyo Co., Ltd | Humanized antibodies reacting with the ganglioside GM2 |
| US5874560A (en) * | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
| CA2321093A1 (en) | 1998-02-20 | 1999-08-26 | The Rockefeller University | Apoptotic cell-mediated antigen presentation to dendritic cells |
| AU8026800A (en) | 1999-10-15 | 2001-04-30 | Baylor Research Institute | Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses |
| US7015205B1 (en) * | 1999-10-18 | 2006-03-21 | St. Vincent's Hospital And Medical Center Of New York | Melanoma vaccine and methods of making and using same |
| DK1448229T3 (da) * | 2001-11-29 | 2010-03-08 | Dandrit Biotech As | Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr |
| GB0130720D0 (en) * | 2001-12-21 | 2002-02-06 | Serono Internat S A | Proteins |
| CN1443778A (zh) * | 2002-03-13 | 2003-09-24 | 上海中信国健药业有限公司 | 一种黑色素瘤相关抗原的单克隆抗体及其用途和药物组合物 |
| US20060140983A1 (en) * | 2004-10-25 | 2006-06-29 | Baylor Research Institute | Dendritic cells loaded with heat shocked melanoma cell bodies |
| WO2007016340A2 (en) * | 2005-07-29 | 2007-02-08 | Providence Health System | Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response |
| EP1951318B1 (en) * | 2005-11-07 | 2012-10-17 | British Columbia Cancer Agency | Inhibition of autophagy genes in cancer chemotherapy |
| MY160857A (en) * | 2006-02-03 | 2017-03-31 | Malaysian Palm Oil Board | A cancer vaccine |
| AR060424A1 (es) | 2007-04-11 | 2008-06-18 | Consejo Nac Invest Cient Tec | Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento |
| GB0713116D0 (en) * | 2007-07-06 | 2007-08-15 | Therapeutics Ltd E | Treatment of melanoma |
| CN105288602A (zh) | 2011-10-20 | 2016-02-03 | 新干细胞肿瘤学有限责任公司 | 具有γ干扰素的抗原呈递癌症疫苗 |
-
2012
- 2012-10-22 CN CN201510706438.6A patent/CN105288602A/zh active Pending
- 2012-10-22 JP JP2014537358A patent/JP2014530627A/ja active Pending
- 2012-10-22 HK HK15101637.0A patent/HK1201176A1/xx unknown
- 2012-10-22 US US14/352,983 patent/US9555058B2/en not_active Expired - Fee Related
- 2012-10-22 SG SG11201401631VA patent/SG11201401631VA/en unknown
- 2012-10-22 SG SG10201602424RA patent/SG10201602424RA/en unknown
- 2012-10-22 KR KR1020147013353A patent/KR20150016200A/ko not_active Withdrawn
- 2012-10-22 WO PCT/US2012/061306 patent/WO2013059784A1/en not_active Ceased
- 2012-10-22 AU AU2012325764A patent/AU2012325764A1/en not_active Abandoned
- 2012-10-22 AU AU2012325758A patent/AU2012325758A1/en not_active Abandoned
- 2012-10-22 CA CA2852960A patent/CA2852960A1/en not_active Abandoned
- 2012-10-22 EP EP12841839.9A patent/EP2768519A4/en not_active Withdrawn
- 2012-10-22 CN CN201610218244.6A patent/CN105861437A/zh not_active Withdrawn
- 2012-10-22 EP EP12842230.0A patent/EP2768534A4/en not_active Withdrawn
- 2012-10-22 WO PCT/US2012/061294 patent/WO2013059778A2/en not_active Ceased
- 2012-10-22 US US14/352,982 patent/US20140308316A1/en not_active Abandoned
- 2012-10-22 CN CN201610301904.7A patent/CN105999249A/zh active Pending
- 2012-10-22 HK HK15101635.2A patent/HK1201175A1/xx unknown
- 2012-10-22 SG SG11201401632WA patent/SG11201401632WA/en unknown
- 2012-10-22 CN CN201280051799.6A patent/CN103917246A/zh active Pending
- 2012-10-22 CA CA2852967A patent/CA2852967A1/en not_active Abandoned
- 2012-10-22 JP JP2014537355A patent/JP2014533938A/ja active Pending
- 2012-10-22 SG SG10201508535RA patent/SG10201508535RA/en unknown
- 2012-10-22 KR KR1020147013355A patent/KR20150004791A/ko not_active Withdrawn
- 2012-10-22 CN CN201280051821.7A patent/CN103957925A/zh active Pending
-
2014
- 2014-04-22 IL IL232173A patent/IL232173A0/en unknown
- 2014-04-22 IL IL232172A patent/IL232172A0/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080031900A1 (en) * | 2006-06-30 | 2008-02-07 | Baylor Research Institute | Dendritic Cells Generated Using GM-CSF and Interferon Alpha and Loaded with Heat-Treated and Killed Cancer Cells |
| US20090041792A1 (en) * | 2007-07-19 | 2009-02-12 | Istituto Superiore Di Sanita | Dendritic cells, uses therefor, and vaccines and methods comprising the same |
Non-Patent Citations (1)
| Title |
|---|
| DILLMAN RO等: "Phase II trial of Dentritic Cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report", 《CANCER BIOTHERAPY AND RAPIOPHARMACEUTICALS》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118441033A (zh) * | 2024-04-24 | 2024-08-06 | 广西医科大学 | HLA-DPB1*05:01在抗γ干扰素自身抗体所致获得性免疫缺陷筛查中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL232173A0 (en) | 2014-06-30 |
| NZ623917A (en) | 2016-09-30 |
| SG11201401631VA (en) | 2014-05-29 |
| WO2013059778A3 (en) | 2013-07-04 |
| EP2768534A4 (en) | 2015-04-01 |
| KR20150004791A (ko) | 2015-01-13 |
| EP2768534A1 (en) | 2014-08-27 |
| JP2014530627A (ja) | 2014-11-20 |
| JP2014533938A (ja) | 2014-12-18 |
| HK1201175A1 (en) | 2015-08-28 |
| NZ623915A (en) | 2016-02-26 |
| SG10201602424RA (en) | 2016-05-30 |
| EP2768519A2 (en) | 2014-08-27 |
| WO2013059784A1 (en) | 2013-04-25 |
| SG10201508535RA (en) | 2015-11-27 |
| US9555058B2 (en) | 2017-01-31 |
| SG11201401632WA (en) | 2014-05-29 |
| CA2852960A1 (en) | 2013-04-25 |
| CN103917246A (zh) | 2014-07-09 |
| US20140308316A1 (en) | 2014-10-16 |
| CN103957925A (zh) | 2014-07-30 |
| CN105861437A (zh) | 2016-08-17 |
| CA2852967A1 (en) | 2013-04-25 |
| EP2768519A4 (en) | 2015-07-01 |
| WO2013059778A2 (en) | 2013-04-25 |
| CN105999249A (zh) | 2016-10-12 |
| HK1201176A1 (en) | 2015-08-28 |
| IL232172A0 (en) | 2014-06-30 |
| AU2012325758A1 (en) | 2014-04-24 |
| KR20150016200A (ko) | 2015-02-11 |
| US20140314814A1 (en) | 2014-10-23 |
| AU2012325764A1 (en) | 2014-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Prue et al. | A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A* 0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer | |
| Gajewski et al. | Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12 | |
| Kim et al. | Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma | |
| Palucka et al. | Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity | |
| Escobar et al. | Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients | |
| Hatfield et al. | Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy | |
| Schreibelt et al. | Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells | |
| Davis et al. | Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients | |
| US9555058B2 (en) | Antigen presenting cancer vaccine | |
| Li et al. | Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy | |
| US6699483B1 (en) | Cancer treatments | |
| CN101511384A (zh) | 采用GM-CSF和α干扰素制成的并装载热处理的且杀死的癌细胞的树突状细胞 | |
| Ramanathan et al. | Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer-a feasibility study | |
| Flores et al. | Dendritic Cells Loaded with Heat Shock‐Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell‐Dependent Antitumor Immune Responses In Vitro | |
| EP2809775B1 (en) | Pluripotent germ layer origin antigen presenting cancer vaccine | |
| JP4592702B2 (ja) | ＮＹ−ＥＳＯ−１とアジュバントのｉｎｖｉｖｏ有効性 | |
| Radej et al. | Immunomodelling characteristics of mature dendritic cells stimulated by colon cancer cells lysates | |
| Park et al. | Efficient antitumor immunity in a murine colorectal cancer model induced by CEA RNA‐electroporated B cells | |
| Gustafson et al. | Therapeutic vaccines for malignant brain tumors | |
| HK1230080A1 (en) | Antigen presenting cancer vaccine with gamma interferon | |
| NZ623917B2 (en) | Antigen presenting cancer vaccine | |
| CN118086212A (zh) | 新冠病毒表位多肽致敏的树突状细胞及其应用 | |
| Blood | Melanoma Patients with MAGE-3 or+ Immunization of HLA-A2 | |
| Cho et al. | Development of optimal guideline for effective dendritic cell immunotherapy in mouse melanoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160203 |